Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

PHASE4RecruitingINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Acute PainChronic PainPostoperative Pain
Interventions
DRUG

Liposomal bupivacaine

Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).

DRUG

Bupivacaine Hydrochloride

Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)

Trial Locations (1)

4000000

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

All Listed Sponsors
collaborator

People's Hospital of Chongqing

OTHER

collaborator

LanZhou University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Shapingba District People's Hospital of Chongqing

UNKNOWN

lead

The Second Affiliated Hospital of Chongqing Medical University

OTHER